Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
Chonnam Medical Journal · 2017 · 53 (3) · 173
DOI: 10.4068/cmj.2017.53.3.173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chonnam Medical Journal, 2017. Verfasst von Sunhyo Ryu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Colorado Denver Medical School, Aurora, Colorado, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Melanoma is one of the most aggressive cancers in the world and is responsible for the majority of skin cancer deaths. Recent advances in the field of immunotherapy using active, adoptive, and antigen-specific therapeutic approaches, have generated the expectation that these technologies have the potential to improve the treatment of advanced malignancies, including melanoma. Treatment options for metastatic melanoma patients have been dramatically improved by the FDA approval of new therapeutic agents including vemurafenib, dabrafenib, and sorafenib. These kinase inhibitors have the potential to work in tandem with MEK, PI3K/AKT, and mTOR to inhibit the activity of melanoma inducing BRAF mutations. This review summarizes the effects of the new therapeutic agents against melanoma and the underlying biology of these BRAF inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, University of Colorado Denver Medical School, Aurora, Colorado, USA.
- Department of Premedical Sciences, Chosun University School of Medicine, Gwangju, Korea.
Zitieren
APA
Ryu, S., Youn, C., Moon, A. R., Howland, A., Armstrong, C. A., & Song, P. I. (2017). Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Medical Journal, 53(3), 173. https://doi.org/10.4068/cmj.2017.53.3.173
Vancouver
Ryu S, Youn C, Moon AR, Howland A, Armstrong CA, Song PI. Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Medical Journal. 2017;53(3):173. doi:10.4068/cmj.2017.53.3.173
BibTeX
@article{Ryu2017,
author = {Ryu, Sunhyo and Youn, Chakyung and Moon, Ae Ran and Howland, Amanda and Armstrong, Cheryl A and Song, Peter I},
title = {Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma},
journal = {Chonnam Medical Journal},
year = {2017},
volume = {53},
number = {3},
pages = {173},
doi = {10.4068/cmj.2017.53.3.173}
}
EUVIMED